Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising results in initial clinical assessments . Recent https://ragingbookmarks.com/story21369608/retatrutide-emerging-research-and-possible-therapeutic-applications